




RealRate

PHARMACEUTICAL 2019

Sonoma Pharmaceuticals Inc.
Rank 271 of 371



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai



PHARMACEUTICAL 2019

Sonoma Pharmaceuticals Inc.
Rank 271 of 371



The relative strengths and weaknesses of Sonoma Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sonoma Pharmaceuticals Inc. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 396% points. The greatest weakness of Sonoma Pharmaceuticals Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 340% points.

The company's Economic Capital Ratio, given in the ranking table, is -358%, being 27% points below the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	16,254
Cost of Goods Sold	9,348
Intangible Assets	0
Liabilities, Current	3,261
Liabilities, Non-Current	32
Other Assets	1,816
Other Compr. Net Income	0
Other Expenses	40
Other Liabilities	587
Other Net Income	-99
Property and Equipment	1,136
Research and Development	1,575
Revenues	16,658
Selling, General and Administrative Expense	19,924

Output Variable	Value in 1000 USD
Assets	19,206
Liabilities	3,880
Expenses	30,887
Stockholders Equity	15,326
Net Income	-14,328
Comprehensive Net Income	-14,328
Economic Capital Ratio	-358%

